Abstract: The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided is an antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications.

Abstract: The present invention provides QMAX based devices, kits, and methods for rapid, easy to use, and/or inexpensive detection of assaying.

Abstract: Compounds useful as fluorescent or colored dyes are disclosed. The compounds have the following structure (I): or a stereoisomer, tautomer or salt thereof, wherein R1, R2, R3, R4, R5, L1, L2, L3, L4, M, m and n are as defined herein. Methods associated with preparation and use of such compounds are also provided.

Abstract: Biomarkers tests which can be used to predict a positive or negative risk of preeclampsia are described. More specifically, a panel of biomarkers including MMP-7 and gpIIbIIIa, described. The test is useful to predict preeclampsia when a biological sample is obtained between the 16th and 22nd week of pregnancy. Prediction later in pregnancy can be achieved by a combination of Siglec-6, Activin A, ALCAM, and/or FCN2.

Abstract: The disclosure provides synthetic immune receptors (SIRs), nucleic acids encoding the SIRs, methods of making and using the SIRs, in, for example, adoptive cell therapy.

Abstract: The invention features combination therapies using an IL-15-based superagonist complex and an antibody to effectively treat subjects with cancer and infectious diseases.

Abstract: The therapeutic or healthful aspect of nutritional supplements, dietary supplements, and drugs has been significantly improved synergistically through infusion of paraprobiotics (inactivated or attenuated or killed probiotics) along with their immunomodulins or postbiotics, especially those of genus Lactobacillus, Bacillus, Lactococcus, Pediococcus, Propionibacterium, Enterococcus, Streptococcus, Penicillium, and Brevibacterium. The objection of using live probiotic bacteria as adjuvants in combination with the nutraceuticals, dietary supplements and drugs by the medical practitioners has been obviated through use of paraprobiotics along with their postbiotics to improve health or treat a specific disease.

Abstract: A method and system to make a modular microfluidic device in a miniaturized form for cell culture, co-culture, and organ-on-a-microfluidic device as in-vitro model of human organs within compartmentalized 3D structures is described. The modular microfluidic device enables co-culturing of heterogeneous cell assemblies that are adjacent or sequentially connected to promote enhanced cell-cell interaction. In vivo-like flow into and/or from one cell growth chamber to adjacent cell growth chamber is maintained by micro-engineered porous barriers i.e., porous walls and membranes. These porous barriers provide a tool for mimicking the paracrine exchange between cells in the human body. The system comprises of a set of microelectrodes for real-time and long-term monitoring and quantitative measurement of the impact of stimuli on the epithelial tissue permeability.

Abstract: Methods for detecting presence of one or more of Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumooniae, Toxoplasma gondii, Moraxella catarrhalis, Escherichia coli, Shigella, Staphylococcus aureus, Pneumocystis jirovecii, Chlamydia trachomatis, Ureaplasma urealyticum, Ureaplasma parvum, Ureaplasma spp., Bartonella spp., Streptococcus agalactiae, and Neisseria meningitidis nucleic acids in a sample, such as a biological sample obtained from a subject, or an environmental sample, are provided. This disclosure also provides probes, primers, and kits for detecting one or more of Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, Toxoplasma gondii, Moraxella catarrhalis, Escherichia coli, Shigella, Staphylococcus aureus, Pneumocystis jirovecii, Chlamydia trachomatis, Ureaplasma urealyticum, Ureaplasma parvum, Ureaplasma spp., Bartonella spp., Streptococcus agalactiae, and Neisseria meningitidis in a sample.

Abstract: Described herein are methods for quantifying IAIP levels in a sample.

Abstract: Described herein are methods, compositions and kits directed to amplification of nucleic acids suitable for both next generation sequencing (NGS) and a second round of sequencing as validation, such as Sanger sequencing.

Abstract: Current invention relates to a polynucleotide encoding activating chimeric receptors comprising engineered Natural Killer Group 2 member C (NKG2C) having enhanced affinity for HLA class I histocompatibility antigen alpha chain E (HLA-E)/peptide complex or an extracellular receptor domain of NKG2A coupled to an effector domain. It also relates to NK cells expressing such constructs and the use of these NK cells to induce cytotoxicity. It further exemplifies that the NK cells expressing polynucleotide encoding NKG2C (SIIS)/CD94/DAP12 or NKG2C/CD94/4-1 BB/CD3z showed enhanced NK cytotoxicity against cancer cells.

Abstract: Aspects of the application provide methods of identifying and sequencing proteins, polypeptides, and amino acids, and compositions useful for the same. In some aspects, the application provides methods of obtaining data during a degradation process of a polypeptide, and outputting a sequence representative of the polypeptide. In some aspects, the application provides amino acid recognition molecules having a shielding element that enhances photostability in polypeptide sequencing reactions.

Abstract: Disclosed herein are methods of detecting a target nucleic acid sequence, determining the localization of the target nucleic acid sequence, and/or quantifying the number of target nucleic acid sequences in a cell. This method may be used on small target nucleic acid sequences, and may be referred to as Nano-FISH.

Abstract: A method for diagnosing or prognosing, multiple sclerosis including the steps of (a) measuring the amount of at least one first protein as set forth in SEQ ID NO: 1, the at least first protein belonging to the group of proteins: a first protein, a second protein, a third protein, a fourth protein and a fifth protein, as set forth in SEQ ID NO 1 to 5, (b) comparing the amount of the at least first protein with the amount of the same protein in a control sample, and (c) determining the status of the biological sample.

Abstract: The invention relates to proteins that contain the CD4 domain 1 and the CD4 domain 2 (CD4 D1D2), wherein the CD4 D1D2 contains one or more mutations compared to wild-type human CD4 D1D2, and to methods of using the proteins for treating a human immunodeficiency virus (HIV) infection in a subject.

Abstract: A method for aligning a sample to an array is provided. An image of sample image of a sample can be received by a data processor. The sample image having a first resolution. An array image including an overlay of an array with the sample and an array fiducial can be received by the data processor. The array image having a second resolution lower than the first resolution of the sample image. The sample image can be registered to the array image by aligning the sample image and the array image. An aligned image can be generated based on the registering. The aligned image can include an overlay of the sample image with the array. The aligned image can be provided by the data processor. A method for detecting fiducials associated with an array is provided. Systems and non-transitory computer readable mediums performing the method are also provided.

Abstract: The present disclosure includes a multiplexed peptide assay to generate an epitope-resolved view of antibody reactivity across all human coronaviruses (CoVs). PepSeq accurately classifies SARS-CoV-2 exposure status and reveals epitopes across the Spike and Nucleocapsid proteins. Two of these represent recurrent reactivities to conserved, functionally-important sites in the S2 subunit of Spike, regions that we show are also targeted for the endemic CoVs in pre-pandemic controls. At one of these sites, we demonstrate that the SARS-CoV-2 response strongly and recurrently cross-reacts with the endemic virus hCoV-OC43. The disclosed epitope-resolved analysis reveals new CoV targets for the development of diagnostics, vaccines and therapeutics, including a site that may have broad neutralizing potential.

Abstract: The present invention refers to a new monoclonal antibody or fragment thereof, called 14F5F6, which specifically recognizes herpes simplex virus (HSV), in its two types, herpes simplex virus type 1 and herpes simplex virus type 2 (HSV-1 and HSV-2). Preferably, the antibody of the invention is useful for the development of methods for the diagnosis of herpes simplex virus infection, as well as for the production of pharmaceutical compositions intended for the treatment, protection and/or prophylaxis of infection specifically caused by HSV-1 and HSV-2.

Abstract: A motion detector adapted to detect activity of extremely small scale organisms, such as micro-organisms, bacteria and fungi, and even of viruses and genetic material, such as DNA and RNA. The motion detector is capable of detecting nano-motion, that is, motion in the order of nanometers or less.

Abstract: Ex vivo cell-based living biosensors, methods of imaging and identifying cell types and/or cell phenotypes, and uses of the systems and methods are provided.

Abstract: The invention disclosed herein provides methods and materials useful in gene therapy regimens designed to inhibit myelination abnormalities that occur in the urea cycle disorder arginase deficiency. The underlying cause of the progressive neurological dysfunction that occurs in this disorder has been previously unknown and conventional therapies, at best, only slow the onset of neurological dysfunction. This neurological dysfunction results at least in part from the dysmyelination that occurs in the central nervous system due to the lack of adequate hepatic expression of arginase 1. We have discovered an origin of this neurological dysfunction and, using this information, designed materials and associated methods of gene therapy. The methods and materials disclosed herein can inhibit and essentially prevent neurological dysfunction in a murine model of arginase deficiency.

Abstract: The present invention provides compounds used in the synthesis of chemiluminescent acridinium compounds and methods of producing these compounds. Specifically, methods are provided for the N-alkylation of acridan compounds using alkylating reagents. Typically, these alkylating reagents comprise a protected sulfonate group protected with an acid-labile protecting group.

Abstract: The invention in one aspect relates to recombinant replication competent adenovirus that can replicate in and lyse a host cell comprising in the genome of the adenovirus a coding sequence for a glycogen synthase kinase-3 (GSK3) protein operably linked to an expression control sequence. It also relates, among others, to means and methods for treatment of cancer with a coding sequence for a glycogen synthase kinase-3 (GSK3) protein operably linked to an expression control sequence, preferably in the context of an adenovirus. This work was funded in part by European Union Horizon 2020 research and innovation programme, Marie-Sklodowska-Curie grant number 643130.

Abstract: A technique for expansion microscopy (ExM) utilizing anchorable derivatives of hematoxylin and eosin (H&E) stained tissue specimens within tissue samples, in order to achieve high resolution detection of biomolecules with precise morphological features of cells and nuclei, which in turn, allows for effective for accurate early stage disease diagnosis including various cancers. Staining with H&E employs anchorable derivatives that can be cross-linked into the ExM hydrogel matrix.

Abstract: The present invention relates to the use of a Raman spectral signature of nitrate, as a biomarker for an early, real-time diagnosis of nitrogen status in growing plants in a non-invasive or non-destructive way in order to detect nitrogen deficiency before the onset of any visible symptoms. The early, real-time diagnosis of nitrogen deficiency in plants makes it possible to correct nitrogen deficiency for the avoidance of negative effects on the yield and biomass of growing plants or leafy vegetables.

Abstract: Numerous embodiments for improving an analog neural memory in a deep learning artificial neural network as to accuracy or power consumption as temperature changes are disclosed. In some embodiments, a method is performed to determine in real-time a bias value to apply to one or more memory cells in a neural network. In other embodiments, a bias voltage is determined from a lookup table and is applied to a terminal of a memory cell during a read operation.

Abstract: Systems and methods for detection of biological agents are generally described. Certain embodiments relate to circuits comprising a first semiconductor nanosensor and a second semiconductor nanosensor in electrical communication with the first semiconductor nanosensor. The circuit can be configured to output a differential electrical property between the first semiconductor nanosensor and the second semiconductor nanosensor when exposed to a sample comprising an analyte. In certain instances, the first semiconductor nanosensor is functionalized with a detector species, and the second semiconductor nanosensor is not functionalized with the detector species. In some cases, the first semiconductor nanosensor is functionalized with a detector species, and the second semiconductor nanosensor is associated with a gate.

Abstract: An object of the present invention is to provide a measurement method and a reagent for measurement which can measure LRG in a biological sample simply in a short time. The present inventors have intensively studied to achieve the object and made findings that LRG in a biological sample can be measured simply in a short time by an immunoagglutination measurement method in which the biological sample is brought into contact with insoluble carrier particles carrying a first anti-LRG monoclonal antibody and insoluble carrier particles carrying a second anti-LRG monoclonal antibody in a liquid phase, and the invention has been thus completed.

Abstract: The present disclosure relates to, inter alia, devices, systems, and methods for use in the magnetic separation of biological entities from fluid samples. This device includes a magnetic separation chamber configured to receive a fluid sample for magnetic separation, where the magnetic separation chamber includes at least two magnets mounted on the surface or in the wall of the magnetic separation chamber. The device also includes a force provider configured to move the magnetic separation chamber in a side-to-side motion to mix and/or magnetize the fluid sample. In one embodiment, the magnetic separation chamber is in a form of a sleeve and comprises a substantially central channel for loading a vessel containing the fluid sample therein. The systems and methods of the present disclosure involve the use of this device to separate biological entities from fluid samples.

Abstract: Provided herein are anti-FLT3L antibodies and methods of using the antibodies to treat autoimmune and other inflammatory diseases.

Abstract: Disclosed is a method for detecting a target substance, comprising: forming on a carrier a complex comprising Wisteria floribunda lectin (WFA) and a target substance by mixing the WFA immobilized on the carrier with the target substance comprising a sugar chain that binds to the WFA in the presence of an alcohol having 1 to 7 carbon atoms consisting of carbon atoms, hydrogen atoms, and oxygen atoms; and detecting the target substance by detecting the complex.

Abstract: Disclosed is an apparatus for monitoring bioaerosols, which includes a capturer configured to capture bioaerosol particles in air in a capture solution; a first droplet discharger configured to electro-spray the capture solution, in which the particles are captured, in a form of first droplets; a second droplet discharger configured to electro-spray a reagent, capable of reacting with the particles of the first droplets, in a form of second droplets; a reactor in which the first and second droplets are mixed so that the particles react with the reagent; and a measurer configured to measure the particles reacted with the reagent, wherein a size of the first droplets discharged from the first droplet discharger is controlled such that the particles are individually included in the first droplets. In accordance with such a configuration, individual particles can react with a reagent, which allows accurate bioaerosol monitoring optically.

Abstract: A testing system for conducting electrochemistry analysis of a specimen sample is provided. The testing system includes a testing receptacle device and a diagnostic device. The testing receptacle device includes a receptacle having an interior space defined therein and a lid configured to be secured on an upper end of the receptacle. The lid includes an opening extending into the receptacle and a cartridge slot for receiving a test sensor cartridge having a functionalized electrode strip with an electrode well contact point provided thereon. The diagnostic device is configured as a potentiostat or similar device and includes a docking port for receiving a lower end of the testing receptacle device. The testing system is configured for receiving a specimen sample through the opening in the receptacle lid and placing the specimen sample in contact with the electrode well contact point of the functionalized electrode strip.

Abstract: The present invention relates to a multispecific antibody comprising at least one CD137 binding domain and at least one PDL1 binding domain, and pharmaceutical compositions and methods of use thereof. The present invention further relates to a nucleic acid encoding said multispecific antibody, a vector comprising said nucleic acid, a host cell comprising said nucleic acid or said vector, and a method of producing said multispecific antibody.

Abstract: The present disclosure based on the inventors' recognition that PAN domain containing proteins play important immune regulating functions. Disclosed herein are methods for modulating immune responses in plants and animals, improving in vitro fertilization efficiency, and inhibiting human cell division and cellular migration in cancer cells. Also disclosed herein are genetically modified plants that are resistant to pathogenic infections.

Abstract: Provided herein is a nucleic acid detection system comprising: a CRISPR system comprising an effector protein and one or more guide RNAs designed to bind to corresponding target molecules; an RNA-based masking construct; and optionally, nucleic acid amplification reagents to amplify target RNA molecules in a sample. In another aspect, the embodiments provide a polypeptide detection system comprising: a CRISPR system comprising an effector protein and one or more guide RNAs designed to bind a trigger RNA, an RNA-based masking construct; and one or more detection aptamers comprising a masked RNA polymerase promoter binding site or a masked primer binding site. In some embodiments, the system may be used to detect viruses in samples.

Abstract: Methods, compositions and kits are disclosed directed at levetiracetam derivatives, immunogens, signal generating moieties, antibodies that bind levetiracetam and immunoassays for detection of levetiracetam.

Abstract: The present invention relates to novel compounds that can be employed in the treatment, alleviation or prevention of a group of disorders and abnormalities associated with Tau (Tubulin associated unit) protein aggregates including, but not limited to, Neurofibrillary Tangles (NFTs), such as Alzheimer's disease (AD).

Abstract: Described herein are engineered antigen presenting cells that can be capable of modulating a target T-cell in a T-cell antigen specific manner. In some embodiments, the engineered APCs can include a modified antigen presentation pathway. Also described herein are methods of making and using the engineered antigen presenting cells.

Abstract: An immunoassay platform and methodology are described for discriminatively detecting target microorganism antibodies to a target antigen in a biological sample derived from a host animal, from among antibodies of cross-reactively-related microorganism(s) potentially present in the biological sample, by use of contemporaneous assays conducted with and without blocking antibodies exogenous to the host animal. Attenuation of detection reagent signal between the contemporaneous assays may be used to determine a target antigen previously infected or non-infected status of the host animal.

Abstract: Methods are provided for detecting the amount of one or more CAH panel analytes (i.e., pregnenolone, 17-OH pregnenolone, progesterone, 17-OH progesterone, dehydroepiandrosterone (DHEA), androstenedione, testosterone, deoxycorticosterone, 11-deoxycortisol, and cortisol) in a sample by mass spectrometry. The methods generally involve ionizing one or more CAH panel analytes in a sample and quantifying the generated ions to determine the amount of one or more CAH panel analytes in the sample. In methods where amounts of multiple CAH panel analytes are detected, the amounts of multiple analytes are detected in the same sample injection.

Abstract: Provided herein is an immunogenic composition comprising a synthetic consensus antigen to chondroitin sulfate proteoglycan 4 (CSPG4) protein which is abundant in many cancers. Also disclosed herein is a method of treating a tumor associated pathology in a subject in need thereof, by administering the immunogenic composition to the subject.

Abstract: The present invention provides a recombinant viral vector, an immunogenic composition containing the same, and the use thereof. The recombinant viral vector comprises a polynucleotide encoding a fusion peptide of CD4 helper T cell epitopes, the epitope fusion peptide comprising a cytomegalovirus epitope and/or an influenza virus epitope. The epitope fusion peptide and the recombinant viral vector provided by the present invention can improve the level of cellular immune response to a target immunogen, particularly to a weak immunogen, and overcome the immune tolerance of immune system to an antigen, particularly to a tumor antigen or an infection-related antigen. The products of the present invention are suitable for enhancing the efficacy of vaccines.

Abstract: The present invention provides a method of testing a blood for a macrolide immunosuppressant conveniently and/or highly accurately. Specifically, the present invention provides a method of testing a blood for a macrolide immunosuppressant, including: (a) treating a blood sample containing a macrolide immunosuppressant or a metabolite thereof having a macrolide structure with an acid or an alkali; and (b) measuring a concentration of the macrolide immunosuppressant or the metabolite in the blood sample by using an antibody.

Abstract: A biological hair shape change composition including a macromolecular component, a small molecular component and an alkali agent component is provided. The macromolecular component includes a protease belonging to the class of alkaline proteases, and the small molecular component includes a peptide with reduction activity. Both the macromolecular component and the small molecular component are obtained from a fermentation product of Bacillus licheniformis and a keratin and/or keratin polymer-containing medium. Molecular weights of ingredients in the macromolecular component are greater than or equal to 3 kDa and are 3-1000 kDa, and molecular weights of ingredients in the small molecular component are less than 3 kDa and are 0.01-2.99 kDa.

Abstract: A method for forming a nanopore transistor and a nanopore transistor is provided. The method includes: (a) forming an aperture in a filler material by: (i) providing a fin comprising a semiconductor layer and a top layer; (ii) patterning the top layer to form a pillar; (iii) embedding the pillar in a filler material; (iv) removing the pillar, leaving an aperture; (v) lining the aperture with a spacer material; (b) forming a nanopore by etching through the aperture; (b) lining the nanopore with a dielectric, (c) forming a source and a drain by either: between steps a.ii and a.iii, doping the bottom semiconductor layer by using the pillar as a mask, or after step c, filling the aperture with a sealing material, thereby forming a post; removing the filler material; doping the bottom semiconductor layer by using the post as a mask; and removing the sealing material.

Abstract: The present invention pertains to: a marker composition for diagnosing atherosclerosis severity; a composition for diagnosing atherosclerosis severity; an atherosclerosis severity diagnosis kit including the composition; a method for screening substances for preventing or treating atherosclerosis; and a method for providing information about a diagnosis of atherosclerosis severity, wherein LGI3 expression or activity levels are used. According to the present invention, the severity of atherosclerosis can be diagnosed or predicted, and personalized medicine and predictive medicine can be practiced using such information. Moreover, the present invention can treat atherosclerosis without affecting other metabolic phenotypes by administering an LGI3 antagonist.

Abstract: A kit is disclosed for distinguishing between bacterial and viral infections. One of the antibodies of the kit specifically binds to TNF-related apoptosis-inducing ligand (TRAIL) protein and another of the antibodies of the kit specifically binds to Procalcitonin (PCT) protein.

Abstract: The present application provides, in some aspects, methods of treating cancers, such as homologous recombination (HR)-deficient cancers. In some embodiments, the disclosure provides a method for treating cancer by administering to a subject a compound of Formula (I):(I), or a pharmaceutically acceptable salt thereof.